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Abstract 
Significant morphological, clinical and biological prognostic factors vary according to molecular subtypes of breast 
tumors, yet comprehensive analysis of such factors linked to survival in each group is lacking. Clinicopathological 
and micro-environmental criteria, estrogen (ER), progesterone (PR) receptors, HER2, Ki67, basal markers, CD24, CD44, 
ALDH1, BCL2, E-Cadherin and Trio were assessed in 1070 primary operable breast cancers from a single center accord-
ing to five main molecular subtypes and associations with distant metastasis-free survival (DMFS) were examined. 
There were 682 (64 %) luminal A (LA), 166 (16 %) Luminal B HER2 negative (LBH−), 47 (4 %) Luminal B HER2 positive 
(LBH+), 108 (10 %) triple negative (TN) and 67 (6 %) HER2-enriched tumors (H2+). Median follow-up was 13.7 years. 
At 5 years, DMFS in LA (90 %) was better than in LBH− (80.9 %), hazard ratio (HR) = 2.22 [1.44–3.43] P < 0.001; LBH+ 
(74.5 %), HR = 3.14 [1.69–5.84] P < 0.001, TN (71.5 %) HR = 3.63 [2.34–5.63], P < 0.001; and H2+ (65.2 %), HR = 4.69 
[2.90–7.59], P < 0.001. In multivariable analysis, factors associated with shorter DMFS varied according to molecular 
subtype, with tumor size being associated with shorter DMFS in the LBH−, LBH+ and TN groups and the Rho GEF Trio 
and BCL2 phenotypes in TN tumors only. These findings help to define new clinicophenotypic models and to identify 
new therapeutic strategies in the specific molecular subgroups.
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Background
The 2012 WHO classification based solely on the mor-
phological features of breast tumors has limited utility 
for clinical and therapeutic management (Lakhani et  al. 
2012). Perou et  al. classified breast cancers according 
to molecular subtypes: luminal A (LA), luminal B (LB), 
triple-negative (TN), HER2-enriched (H2+) and normal 
breast-like tumors (Perou et  al. 2000). However, about 
half of the HER2 overexpressing tumors are ER-posi-
tive and fall into the LB subtype, the normal breast-like 
group seems to be an artifact, and ER-negative tumors 
encompass at least three other molecular subgroups: the 
molecular apocrine (MA) breast tumor group, the inter-
feron-rich subgroup and the claudin-low subtype.
While several studies have demonstrated the prognos-
tic value of the intrinsic classification (Sorlie et al. 2001) 
or of morphological, clinical or biological prognostic fac-
tors according to molecular type (Maiorano et  al. 2010; 
Pages et  al. 2010; Rajput et  al. 2008; Tan et  al. 2011), 
most studies have presented only one type of criteria, 
for example micro-environmental (Maiorano et al. 2010; 
Pages et al. 2010; Rajput et al. 2008; Tan et al. 2011), bio-
logical (Lane et al. 2008) or immunohistochemical (Blows 
et  al. 2010; Cheang et  al. 2008, 2009). Furthermore, for 
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the immunohistochemical criteria, only certain antibod-
ies in certain molecular groups are presented (Charpin 
et al. 2009; Dawson et al. 2010; Kim et al. 2011; Morrison 
et al. 2008), or only for one molecular subtype (Cheang 
et al. 2009).
Here, we report a comprehensive prognostic analysis 
that integrates clinicopathological criteria, micro-envi-
ronmental parameters and selected immunohistochemi-
cal markers focusing on the five main molecular groups 
of breast cancers Luminal A (LA), Luminal B HER2-neg-
ative (LBH−), Luminal B HER2-positive (LBH+), Triple 
negative (TN) and HER2-enriched (H2+) as defined by 
Goldhirsch et  al. (2013) and Maisonneuve et  al. (2014). 
For each molecular group, we describe parameters, iden-
tify particular sub-phenotypes [Basal (CK5/6 and/or 
vimentin and/or EGFR positive), Claudin-low (CD24−/
CD44+ and/or ALDH1 positive), E-Cadherin, Trio and 




Between 1989 and 1993, 1634 patients with primary 
operable invasive breast carcinoma were operated on and 
monitored at our institution. Tissue microarray (TMA) 
blocks were built for immunohistochemical analyses 
and 1070 cases were available for our study [969 invasive 
ductal carcinomas, not otherwise specified (IDC-NOS) 
and 101 invasive lobular carcinomas (ILC)]. Median fol-
low-up was 13.7  years [95  %CI (3.6–14)]. Patients were 
operated on, either by a modified radical mastectomy 
(260 cases) or local tumor resection (810 cases), with axil-
lary node dissection in 1037 cases (98 %). Post-operative 
breast irradiation was performed in 835 cases. Adjuvant 
therapy with chemotherapy and/or hormone therapy was 
decided according to nodal status and hormone receptor 
determination results. Chemotherapy regimens included 
cyclophosphamide, methotextrate, 5-fluorouracil or epi-
rubicin, vincristine, methotextrate; or mitomycin-C, 
thiotepa, vindesin. All patients were followed in a single 
large referral center. Institutional review board approval 
was obtained for this retrospective study in accordance 
with national laws.
Classical and micro‑environmental pathological 
parameters
Classical and micro-environmental parameters that had 
been prospectively entered in a breast cancer data base 
were available for analysis. The largest macroscopic and/
or microscopic tumor size, and only definite peritumoral 
invasion were taken into account. Mitotic index was cal-
culated as a function of the number of observed mitoses 
in 10 high-power fields (X400): scores 1, 2 and 3 were 
respectively associated with <5, 5–15 and >15 mitoses. 
The median number of lymph nodes examined per case 
was 14 (range 2–35). Inflammation, fibrosis, elastosis or 
necrosis, evaluated on whole tissue sections ≥50 % were 
considered as marked.
TMA and immuno‑histochemical assay
Eleven IDC-NOS and six ILC tissue microarray blocks 
were constructed. For each case, four (for IDC-NOS) 
and six (for ILC) 0.6  mm cores were performed. Every 
TMA block from the 1070 patients was re-cut into 4 μm 
sections mounted on SuperFrost® slides. Full details on 
immunohistochemisty processes are detailed in Addi-
tional file  1: Annex A. We also tested Trio, a complex 
protein activating Rho-GTPases which plays a role in cell 
adhesion, motility and invasion through the control of 
actin cytoskeleton remodeling.
Interpretation of immuno‑histochemical assays
Tumors were considered as positive for estrogen (ER) and 
progesterone (PR) receptors when ≥1 % of cells showed 
expression and for HER2 if the Her2 immunostain 
showed 3+ staining intensity. For 2+ scores (n  =  38), 
whole tissue sections were reviewed and among them, 
17 tumors were re-evaluated as 3+ and 21 as 2+. FISH 
analysis was not performed in these 21 cases (1.8 % of the 
study population) as it is not interpretable in Hollande-
fixed tumors. In these 21 cases we inferred their HER2 
status based on our previous studies: tumors with more 
than 60 % of 2+ positive tumor cells were considered as 
HER2 positive (Chibon et  al. 2009). Two cut-offs of 14 
and 19  % were chosen for Ki67 classifications (Maison-
neuve et al. 2014). Cases were categorized as basal immu-
nophenotype when at least one out of the three markers 
(CK5/6, EGFR, and vimentin) was positive. Expression 
of other markers was considered as positive when 1 % or 
more of cells expressed them.
Definition of the phenotypic groups
The five main phenotypic groups according to the Saint 
Gallen (Goldhirsch et al. 2013) classification modified by 
Maisonneuve et al. (2014) are as follows:
LA: ER positive, HER2 negative and Ki67  <  14  % or 
14 % ≤ Ki67 ≤ 19 % and PR ≥ 20 %;
LBH−: ER positive, HER2 negative and Ki67  >  19  % 
or 14 % ≤ Ki67 ≤ 19 % and PR < 20 %; LBH+: ER posi-
tive and HER2 positive, TN: ER and PR negative and 
HER2 negative, and H2+: ER and PR negative and HER2 
positive.
Within the five main molecular groups, we also 
sought to describe tumors by other sub phenotypes: 
basal (CK5/6 and/or vimentin and/or EGFR positive), 
Claudin-low (CD24−/CD44+ and/or ALDH1 positive), 
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E-Cadherin, Trio and BCL2 phenotypes. Thus, the 
TN group was further divided into basal-like (ER/PR/
HER2 negative, CK5/6 and/or vimentin and/or EGFR 
positive (Nielsen et al. 2004)) or non-basal-like (ER/PR/
HER2 negative, CK5/6, vimentin and EGFR negative) for 
descriptive purposes.
Statistical considerations
We compared the χ2 values of data from the five molecu-
lar subgroups. Comparisons were made in the ER/PR 
positive groups (LA vs. LBH−, LA vs LBH+, LBH− vs 
LBH+), in the ER/PR negative groups (TN vs. H2+) and 
the HER2 positive groups (LBH+ vs H2+), and overall 
between the five main phenotypic groups. Quantitative 
data was transformed into categorical variables and when 
cases were not sufficient for inter-category comparisons, 
category regroupings were made based on clinical justifi-
cations. Median follow-up was calculated by the reverse 
Kaplan–Meier method where deaths are censored and 
survival was recorded as the time between treatment 
and the last news or death. All distant metastatic events 
were taken into account for DMFS analysis and patients 
with no metastases (alive or deceased) were censored 
at the date of last news or death. Risk proportionality 
was tested with the residuals test. As DMFS risk var-
ies over time, two Cox models were fitted over different 
time periods: the first 5  years then after 5  years, corre-
sponding approximately to the median time to first event 
(Bellera et  al. 2010). Five-year DMFS was calculated for 
all patients, and 10-year DMFS was calculated only for 
patients with no events in the first time period, and thus 
considered still at risk.
Univariate and multivariate analyses were calculated 
with hazard ratios (HR) and a Cox model for DMFS over 
the two time periods with no risk proportionality viola-
tions. Only variables significant at 0.05 in the univariate 
were maintained in the multivariate models which used a 
stepwise ascending maximum likelihood method.
Results
Among the 1070 breast tumors, 682 (64  %) were Lumi-
nal A (LA), 166 (16  %) were Luminal B HER2 negative 
(LBH−), 47 (4 %) were Luminal B HER2 positive (LBH+), 
108 (10 %) were triple negative (TN) and 67 (6 %) were 
HER2-enriched tumors (H2+). Among the TN tumors, 
there were 88 (8.5 %) basal-like and 16 (1.5 %) non-basal-
like phenotypes.
Clinicopathological and micro‑environmental features 
across molecular groups
Clinical and morphological features differed signifi-
cantly in the different molecular groups (Additional file 2: 
Tables  S1a–e). Other than ki-67 and PR levels, major 
differences between LA and LBH− were age, tumor size, 
mitotic count, SBR grade, nodal involvement, vascu-
lar invasion, elastosis, necrosis and inflammation. The 
same differences were observed between LA and LBH+; 
nodal status and fibrosis were not significantly differ-
ent in these two molecular groups. LBH+ patients were 
younger and less often node-positive compared to the 
LBH− group. Patients in the H2+ group were older com-
pared to LBH+ patients, their tumors were more often 
grade 3, with a higher mitotic count, more inflammation 
and more necrosis. Clinicopathological features includ-
ing the micro-environment were similar in TN and H2+ 
groups (except, nodal status). Comparisons across the 
five groups revealed several overall differences, for exam-
ple, advanced age of LA patients in general and tumor 
necrosis more frequent in TN and HER2-enriched.
Particular phenotypes within molecular groups
Immunohistochemical parameters within the molecu-
lar groups identifying the five specific phenotypes are 
presented in Table  1. Overall, 201 tumors showed a 
basal phenotype (CK5/6 and/or vimentin and/or EGFR 
positive) (19 %) including 71 (35 %) HR positive and 130 
(65  %) HR negative tumors. The CD24−/CD44+ Clau-
din-low phenotype (CD44+/CD24−/low or ALDH1 
positive) was infrequent in the LBH+ (8.5  %) and H2+ 
(19 %) tumors and more frequent in TN (41 %) tumors. 
The CD24+/CD44− immunophenotype was more fre-
quent in LBH− (27  %) and LBH+ (38  %) than in LA 
(14 %) tumors. There was no difference in expression of 
Trio according to the molecular groups. BCL2 expressed 
significantly more frequently in HR positive than in HR 
negative tumors.
Comparisons between basal-like and non-basal-
like phenotypes in triple negative tumors (Table  2) 
showed that basal tumors were more often prolifera-
tive (Ki67  >  15  %) (P  <  0.001), mSBR grade 3 (<0.001), 
with extensive necrosis (P  =  0.007), marked inflamma-
tion (P = 0.07), CD44+ (70.5 % versus 37 %; P = 0.008), 
CD24−/CD44+ (P  =  0.046), ALDH1 and Trio positive 
(P = 0.11 and P = 0.008, respectively).
Distant metastasis‑free survival at 5 years
The 284 distant metastases (26  %) are presented in 
Table  3. LBH+ patients had the highest metastatic 
rate, followed by H2+, TN and LBH− patients. Meta-
static events were the least frequent in the LA group of 
patients. H2+ and TN (42 and 31 % respectively) appear 
to be associated with higher rates of cerebral metastases 
compared to LA and LBH− and LBH+ molecular groups 
(6, 15 and 20 % respectively).
DMFS in LA (90 %) was better than in LBH− (80.9 %), 
hazard ratio (HR)  =  2.22 [1.44–3.43] P  <  0.001; LBH+ 
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Table 1 Immunohistochemical factors and molecular groups
LA (n = 682) LBH− (N = 166) LBH+ (N = 47) H2+ (n = 67) TN (n = 108)
Estrogen receptor
 0 % 67 (100.0) 108 (100.0)
 1–9 % 14 (2.1) 4 (2.4 %) 5 (10.6 %)
 ≥10 % 668 (97.9) 162 (97.6 %) 42 (89.4 %)
Progesterone receptor
 0 % 92 (13.5) 35 (21.1 %) 16 (34.0 %) 67 (100.0) 108 (100.0)
 1–9 % 45 (6.6) 22 (13.3 %) 8 (17.0 %)
 ≥10 % 540 (79.2) 109 (65.7 %) 22 (46.8 %)
 Not specified 5 (0.7) 1 (2.1 %)
KI-67
 <14 % 611 (89.6) 13 (27.7 %) 12 (17.9) 25 (23.1)
 14–19 % 71 (10.4) 24 (14.5 %) 12 (25.5 %) 15 (22.4) 4 (3.7)
 ≥20 % 142 (85.5 %) 22 (46.8 %) 40 (59.7) 78 (72.2)
 Not specified 1 (0.9)
HER2
 Negative 682 (100.0) 166 (100.0 %) 108 (100.0)
 Positive 47 (100.0 %) 67 (100.0)
CK56/EGFR/VIM (Basal phenotype)
Negative 615 (90.2) 146 (88.0 %) 38 (80.9 %) 23 (34.3) 18 (16.7)
Positive 48 (7.0) 15 (9.0 %) 8 (17.0 %) 42 (62.7) 88 (81.5)
Not specified. 19 (2.8) 5 (3.0 %) 1 (2.1 %) 2 (3.0) 2 (1.9)
ALDH1
 Negative 668 (97.9) 160 (96.4 %) 43 (91.5 %) 55 (82.1) 94 (87.0)
 Positive 10 (1.5) 6 (3.6 %) 4 (8.5 %) 11 (16.4) 14 (13.0)
 Not specified 4 (0.6) 1 (1.5)
CD24
 Negative 452 (66.3) 86 (51.8 %) 20 (42.6 %) 31 (46.3) 69 (63.9)
 Positive 225 (33.0) 80 (48.2 %) 27 (57.4 %) 36 (53.7) 39 (36.1)
 Not specified 5 (0.7)
CD44
 Negative 300 (44.0) 85 (51.2 %) 34 (72.3 %) 35 (52.2) 36 (33.3)
 Positive 364 (53.4) 80 (48.2 %) 13 (27.7 %) 31 (46.3) 69 (63.9)
 Not specified 18 (2.6) 1 (0.6 %) 1 (1.5) 3 (2.8)
CD24 and CD44 (Claudin phenotype)
 CD24−/CD44+ 236 (34.6) 45 (27.1 %) 4 (8.5 %) 13 (19.4) 44 (40.7)
 CD24+/CD44− 95 (13.9) 45 (27.1 %) 18 (38.3 %) 18 (26.9) 14 (13.0)
 Other associations 331 (48.5) 75 (45.2 %) 25 (53.2 %) 35 (52.2) 47 (43.5)
 Not specified 20 (2.9) 1 (0.6 %) 1 (1.5) 3 (2.8)
E-Cadherine
 Negative 86 (12.6) 2 (1.2 %) 4 (8.5 %) 3 (4.5) 7 (6.5)
 Positive 590 (86.5) 164 (98.8 %) 43 (91.5 %) 63 (94.0) 99 (91.7)
 Not specified 6 (0.9) 1 (1.5) 2 (1.9)
TRIO phenotype
 Negative 315 (46.2) 85 (51.2 %) 22 (46.8 %) 31 (46.3) 59 (54.6)
 Positive 352 (51.6) 81 (48.8 %) 24 (51.1 %) 36 (53.7) 48 (44.4)
 Not specified 15 (2.2) 1 (2.1 %) 1 (0.9)
BCL2 phenotype
 Negative 166 (24.3) 58 (34.9 %) 27 (57.4 %) 61 (91.0) 95 (88.0)
 Positive 506 (74.2) 106 (63.9 %) 20 (42.6 %) 6 (9.0) 11 (10.2)
 Not specified 10 (1.5) 2 (1.2 %) 2 (1.9)
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(74.5 %), HR =  3.14 [1.69–5.84] P < 0.001, TN (71.5 %) 
HR  =  3.63 [2.34–5.63], P  <  0.001; and H2+ (65.2  %), 
HR  =  4.69 [2.90–7.59], P  <  0.001 (Fig.  1). DMFS in 
LBH− was better than in H2+, HR  =  2.1 [1.22–3.61] 
P  =  0.007 and not different from LBH+, HR  =  1.41 
[0.72–2.75] P  =  0.3 nor TN, HR  =  1.63 [0.98–2.69] 
P  =  0.056. Survival was not different between LBH+ 
and H2+ patients, HR = 1.49 [0.74–2.99] P = 0.26 and 
between TN and H2+ patients, HR  =  1.29 [0.75–2.22] 
P = 0.35.
In univariate analyses for LA tumors, a poorer DMFS 
over the first 5  years was associated with young age 
(≤40  years), large tumor size (20  mm), higher mSBR 
(grade 2 +  3 versus 1), vascular invasion, axillary nodal 
involvement, CD24 and Trio phenotypes. Abundant 
elastosis, CD24−/CD44+ (Claudin-low phenotype) and 
BCL2 phenotypes were associated with better DMFS 
(Fig.  2). For LBH− tumors, large tumor size (20  mm), 
high SBR grade (grade 3 versus 1 +  2) were associated 
with poorer DMFS (Fig.  3). For LBH+ tumors, large 
tumor size (20 mm), vascular invasion and Claudin-low 
phenotype were associated with poorer DMFS (Fig.  4). 
For TN tumors, a poorer DMFS was associated with 
larger tumor size (>20 mm), axillary nodal involvement, 
Trio and BCL2 phenotypes (Fig.  5). In H2+ tumors, 
axillary nodal involvement was associated with poorer 
DMFS, while presence of inflammation was associated 
with better DMFS (Fig.  6). The basal phenotype in the 
main molecular groups had no prognostic impact.
Multivariate models were constructed including clinical 
and morphological immunophenotypes significant in the 
univariate analyses in each molecular group (Table 3). For 
LA tumors, poorer DMFS was associated with younger 
age (≤40 years) [HR = 3.6 (1.7–7.5), P = 0.004], higher 
mSBR grade (2 or 3) [HR  =  3.2 (1.5–6.9), P  =  0.003], 
vascular invasion [HR = 2.3 (1.4–3.9), P = 0.002], CD24 
expression [HR = 2.3 (1.3–3.8), P = 0.002], Trio expres-
sion [HR = 3.9 (1.2–12.3), P = 0.02], and absence of the 
BCL2 phenotype [HR  =  2.5 (1.5–4.1), P  <  0.001]. For 
LBH− tumors, poorer DMFS was associated with larger 
tumoral size (>20 mm) [HR = 2.4 (1.2–4.8), P = 0.02]. For 
LBH+ tumors poorer DMFS was associated with tumor 
size (>20 mm) [HR = 4.2 (1.3–13.7), P = 0.02], vascular 
invasion [HR = 5.7 (1.6–20.9), P = 0.008] and Claudin-
low phenotype [HR = 6.6 (1.6–27.2), P = 0.009]. For TN 
tumors, larger tumor size [HR = 2.5 (1.2–5.3), P = 0.02], 
Table 2 Immunohistochemical parameters for  basal-like 






 <14 % 12 (75.0) 12 (13.6)
 14–19 % 4 (4.5)
 ≥20 % 4 (25.0) 72 (81.8)
CK5-6/EGFR/VIM (Basal phenotype)
 Negative 16 (100.0)
 Positive 88 (100.0)
ALDH1
 Negative 16 (100.0) 74 (84.1)
 Positive 14 (15.9)
Cd24_pos
 Negative 8 (50.0) 57 (64.8)
 Positive 8 (50.0) 31 (35.2)
CD44
 Negative 10 (62.5) 25 (28.4)
 Positive 6 (37.5) 62 (70.5)
 Not specified 1 (1.1)
CD24 and CD44 (Claudin phenotype)
 CD24−/CD44+ 3 (18.8) 40 (45.5)
 CD24+/CD44− 5 (31.3) 9 (10.2)
 Other associations 8 (50.0) 38 (43.2)
 Not specified 1 (1.1)
E-Cadherine
 Negative 5 (31.3) 1 (1.1)
 Positive 11 (68.8) 87 (98.9)
TRIO phenotype
 Negative 4 (25.0) 53 (60.2)
 Positive 12 (75.0) 34 (38.6)
 Not specified 1 (1.1)
BCL2 phenotype
 Negative 13 (81.3) 79 (89.8)
 Positive 2 (12.5) 8 (9.1)
 Not specified 1 (6.3) 1 (1.1)
Table 3 Metastatic events at 5 years according to molecular groups
LA (n = 682) (%) LBH− (n = 166) (%) LBH+ (n = 47) (%) H2+ (n = 67) (%) TN (n = 108) (%)
Metastases 149 (21.8) 55 (33.1) 20 (42.6) 24 (35.8) 36 (33.3)
Bone 102 (68.4) 38 (69.1) 16 (80) 13 (54.2) 17 (47.3)
Lung 39 (26.7) 26 (47.3) 5 (25) 10 (41.7) 13 (36.1)
Liver 58 (38.9) 25 (45.5) 10 (50) 12 (50.0) 11 (30.6)
Brain 9 (6.0) 8 (14.6) 4 (20) 10 (41.7) 11 (30.6)
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Fig. 1 Distant metastasis-free survival over the first 5 years across five breast cancer molecular groups (n = 1070)
Fig. 2 Association between clinicopathological features, immunohistochemical factors and distant metastasis-free survival over the first 5 years in 
the Luminal A group of breast cancer patients
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nodal involvement [HR = 3.5 (1.6–7.6), P = 0.002], Trio 
[HR = 2.4 (1.1–5.1), P = 0.03], and BCL2 [HR = 3.3 (1.3–
8.4), P =  0.01] phenotypes were associated with poorer 
DMFS. In H2+ tumors, nodal involvement [HR  =  8.0 
(2.4–27.1), P = 0.01] and absence or moderate inflamma-
tion [HR = 3.7 (1.6–8.5), P = 0.004] were associated with 
poorer DMFS.
Distant metastasis‑free survival at 10 years
For patients alive with no distant metastatic events at 
5 years, the 10-year DMFS was similar in LA (90.8 %) and 
LB (83.4 %) patients, HR = 1.4 [0.9–2.1], P = 0.06 (Fig. 7). 
There were too few events after 5  years in the LBH+ 
(n = 8), TN (n = 6) and H2+ (n = 1) subgroups to enable 
analyses. Therefore, data on LBH− and LBH+ patients 
were analyzed in one group called LB.
A poorer DMFS after first 5  years in LA tumors was 
associated with large tumor size (20  mm), and nodal 
involvement (Additional file 3: Table S2a). For LB tumors, 
poorer DMFS was associated with young age (≤40 years), 
nodal involvement and basal phenotype. In multivari-
ate analyses, nodal involvement [HR  =  2.1 (1.4–3.4) 
P  =  0.001] as well as tumor size [HR  =  1.8 (1.1–3.0), 
P  =  0.02] remained significant prognostic factors for 
poorer DMFS in the LA group of patients. Young age was 
the sole independent pejorative factor in the LB group 
[HR = 5.4 (2.4–12.0), P < 0.001].
Discussion
In this study, we show that clinical and morphological 
features as well as survival characteristics of breast can-
cer patients vary significantly across the different molec-
ular groups.
Overall, DMFS over the first 5 years was better in LA 
than in all other groups. There were no DMFS differ-
ences between LA and LB tumors after the first 5 years, 
although it has been reported that Luminal tumors have 
a better 5-year survival than non-Luminal (Blows et  al. 
2010) and that HER2+-enriched tumors have the worst 
survival of all groups (Cheang et  al. 2008). None of the 
ER-negative phenotypes in our study were associated 
with DMFS over 10 years for patients with no events at 
5 years.
In contrast to other reports (Tischkowitz et  al. 2007), 
Cheang et  al. reported poorer survival in TN tumors 
with basal phenotypes compared to TN tumors without 
Fig. 3 Association between clinicopathological features, immunohistochemical factors and distant metastasis-free survival over the first 5 years in 
the Luminal B Her2-negative group of breast cancer patients
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(Cheang et  al. 2008). Similarly, the basal phenotype 
(CK5/6 and or EGFR positive) was associated with 
shorter DMFS in luminal HER2-negative and TN but not 
in the HER2-enriched subgroups (Blows et  al. 2010). In 
our results, the basal phenotype was not associated with 
poorer survival, most likely due to the smaller series size 
than in previous reports.
We tested Trio for the first time in a large series of 
breast cancer and it was independently associated with 
poorer survival in LA and TN tumors. This complex pro-
tein activates the Rho-GTPases, Rac1 and RhoA, by its 
two guanine nucleotide exchange factor (GEF) domains 
(Debant et  al. 1996). Cells expressing the Racl-specific 
amino-terminal guanine nucleotide exchange factor 
domain display more rapid cell spreading, haptotactic 
cell migration and anchorage-independent growth sug-
gesting that Trio regulates both cell motility and cell 
growth (Seipel et al. 1999). Expression of Tgat, an onco-
genic isoform of Trio, induces a strong RhoA activa-
tion and the formation of tumors in a xenograft mouse 
model (Bouquier et al. 2009). Furthermore, breast cancer 
patients with poor prognosis exhibit high levels of Trio 
(Lane et al. 2008).
CD24−/CD44+ tumor cells or ALDH1-positive tumor 
cells were significantly associated with poor survival in a 
recent meta-analysis (Zhou et al. 2010), although ALDH1 
expression alone does not significantly predict outcomes 
(Neumeister et  al. 2010). In our study, the Claudin-low 
phenotype was an independent factor for shorter DMFS 
in the Luminal B HER2-positive group of patients only. 
Elsewhere, the CD24−/CD44+ phenotype was con-
versely associated with a better survival (as in LA, by 
univariate analysis only, in our study). CD24 expres-
sion was a marker of poor prognosis in LA in our study. 
CD44-positive cells represent progenitor-like cells and 
CD24 positive cells represent more differentiated luminal 
epithelial cells (Campbell and Polyak 2007; Honeth et al. 
2008). CD24 plays a role in facilitating metastasis by the 
interaction between tumor cells and platelets or endothe-
lial cells and is also associated with proliferation, adhe-
sion and invasion in MCF-7 breast cancer cells (Kim et al. 
2011) affecting their CXCR4 function (Schabath et  al. 
2006).
In the literature, BCL2 is reported as a favorable prog-
nostic factor in ER-positive breast cancers, that is inde-
pendent of the Nottingham Prognostic index (Callagy 
Fig. 4 Association between clinicopathological features, immunohistochemical factors and distant metastasis-free survival over the first 5 years in 
the Luminal B Her2-positive group of breast cancer patients
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Fig. 5 Association between clinicopathological features, immunohistochemical factors and distant metastasis-free survival over the first 5 years in 
the Triple negative group of breast cancer patients
Fig. 6 Association between clinicopathological features, immunohistochemical factors and distant metastasis-free survival over the first 5 years in 
the Her2-enriched group of breast cancer patients
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et  al. 2008) and adjuvant therapy received (Dawson 
et al. 2010). In our study, the expression of BCL2 was an 
independent favorable factor in LA, and an unfavorable 
prognostic factor in TN. Recently the adverse progno-
sis associated with BCL2 expression in triple negative 
tumors has been recognized (Abdel-Fatah et  al. 2013). 
Furthermore, BCL2 expression in associated with poor 
response to Anthracycline-based chemotherapy in Triple 
negative breast cancers (Bouchalova et al. 2015).
This study presents a few limitations. Firstly, the immu-
nohistochemical results are interpreted on TMA in cases 
where the percentages are low and positivity is not always 
conclusive. Secondly, there have been some changes in 
standard treatment offered for breast cancer since the 
beginning of this study. For example, almost two-thirds 
of our patients did not receive any adjuvant treatment 
which is unlikely to be the case in a more recent cohort.
We have assessed the prognostic significance of CD24 
and CD44, detailed the prognostic value of BCL2 in LA 
and TN, and highlighted the association of Trio and 
shorter survival in TN. Furthermore, multivariate analy-
ses including clinical, tumoral, micro-environmental and 
immunohistochemical criteria revealed relevant negative 
or positive factors in each molecular group. The strength 
of these factors is emphasized in our study as 59 % of ER/
PR-positive patients and 65 % of ER/PR-negative patients 
had no adjuvant therapy. Further work is now needed to 
ascertain how to apply CD24, CD44, BCL2 and Trio in 
relevant molecular groups to define new clinicopheno-
typic models and to identify new therapeutic strategies.
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